HQL
abrdn Life Sciences Investors
NYSE · Financial Services · Asset Management · US
$19.41
−0.82%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +39.4%
- EBITDA
- +30.9%
- EBIT
- +0.3%
- Net income
- +95.7%
- EPS
- +93.6%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026